Eden Biodesign, Ltd. (Liverpool, UK), has confirmed its expansion plans for Eden Biodesign, Inc., the Group’s US subsidiary, with the announcement of a facility in the highly coveted biotech hub, Research Triangle Park, NC.
Eden Biodesign, Ltd. (Liverpool, UK), has confirmed its expansion plans for Eden Biodesign, Inc., the Group’s US subsidiary, with the announcement of a facility in the highly coveted biotech hub, Research Triangle Park, NC.
Building on the recent growth of its UK cGMP facility, Eden Biodesign, Inc., will offer a range of cell line/strain development and early process-development services. Eden Biodesign provides services in support of all major biopharmaceutical production technologies (mammalian, microbial, and viral) and offers a toolbox of expression technologies, some through collaboration with partner companies.
Eden Biodesign is further cementing its commitment to the North American market with the recent appointment of Michael Faughnan as business development director, who will be supporting the company’s expansion into the North American market from Southern California. The company is actively developing technology and marketing collaborations with industry leaders throughout North America.
Eden release (PDF)
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.